MagVenture has announced a partnership with Magnus Medical that is intended to provide its industry-leading MagPro magnetic stimulation system to support an “exciting new chapter” in therapeutic transcranial magnetic stimulation (TMS) through Magnus’ SAINT neuromodulation system.
A company press release notes that SAINT therapy will enable patients to receive a quick, highly effective treatment for major depressive disorder (MDD)—especially in the acute setting, where TMS has been limited in adoption.
SAINT therapy is a US Food and Drug Administration (FDA)-cleared, rapid-acting and non-invasive treatment for treatment-resistant major depression in adults who have failed to achieve satisfactory improvement from prior antidepressant medications. Treatment consists of magnetic resonance imaging (MRI)-guided identification of stimulation targets and a proprietary protocol that condenses treatment to just five days.
“MagVenture’s high-performance intermittent theta burst system supports our innovative SAINT therapy; therefore, we are poised to deliver rapid and effective relief to people who suffer from treatment-resistant depression,” said Christian Gormsen, president and chief executive officer of Magnus. “This collaboration underscores our commitment to advancing the treatment of neuropsychiatric disorders and changing people’s lives.”
“We are excited to enable the expansion of SAINT across the USA powered by MagVenture hardware, as well as installation and service support to ensure customers who offer SAINT will experience the same high-quality and reliable operations for which MagVenture is known,” added Kerry Rome, senior vice president of Sales and Marketing at MagVenture.
The release also states that MagVenture and Magnus will exhibit at the upcoming Clinical TMS Society annual meeting (13–15 June 2024, London, UK), where the SAINT system can be seen firsthand.
